Quantifying Thrombogenicity: A Bioanalytical Protocol for the Absorbance-Based Assessment of Vascular Implants with...

Area of Science:

• Biomaterials Science
• Medical Device Evaluation
• Hemostasis and Thrombosis

Background:

• Assessing thrombogenicity is critical for cardiovascular implants like stents and grafts.
• Standardized methods are needed to evaluate how biomaterials interact with blood.
• Current assays focus on clotting mechanisms rather than biomaterial-specific thrombogenicity.

Purpose of the Study:

• To develop and validate a simple, reproducible in vitro protocol for quantifying biomaterial thrombogenicity.
• To assess the impact of anticoagulants and surface coatings on thrombogenicity.
• To compare the thrombogenicity of various commercial vascular implants.

Main Methods:

• A static, in vitro assay using longitudinally sectioned vascular implants in a 96-well plate.
• Quantification of light absorbance through platelet-rich plasma (PRP) or platelet-poor plasma (PPP) over one hour.
• Evaluation of fibrin formation by measuring plasma opaqueness.

Main Results:

• Demonstrated the relative efficacy of different anticoagulants (e.g., sodium citrate, EDTA, heparin).
• Showcased the effectiveness of vascular coating molecules in reducing stent thrombogenicity.
• Provided a quantitative comparison of thrombogenicity across commercial stents, grafts, and stent-grafts.

Conclusions:

• The developed protocol offers a streamlined, quantitative assessment of thrombogenicity for vascular biomaterials.
• This method provides valuable insights for optimizing biomaterial performance and reducing thrombosis risk in implants.
• The assay is adaptable for evaluating novel materials and surface modifications.